An observational study in Urologic Surgical Procedures, Urinary Bladder, Neurogenic and Urinary Bladder Diseases, sponsored by Washington University School of Medicine. Active, not recruiting at 7 sites in United States. Open to participants aged 4 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by Washington University School of Medicine · Observational
The purpose of this research study is to evaluate an Enhanced Recovery After Surgery (ERAS) protocol in children and young adults undergoing urologic reconstructive surgery. The investigators plan to collect data on speed of recovery (how quickly pain improves, length of time in the hospital, and the need for additional pain control) on patients who receive care under the ERAS protocol and compare it to historical controls.
The purpose of this project is to evaluate Enhanced Recovery After Surgery (ERAS) in the pediatric setting for participants undergoing intraabdominal urologic reconstruction procedures. ERAS practices are being implemented in the department independent of research and this project will allow the investigators to review these practices.
Providers, participants, and family members will complete pre- and post- surgery questionnaires. These questionnaires are geared to collect demographic information about the participant and how the surgery affects their life situation. The providers will answer questions regarding their experience with ERAS.
Evidence-based ERAS principles and procedures are compulsory components of this project. These will be documented in the medical record and are considered standard of care practice as part of perioperative patient care.
Data collected from the medical record for each participant will aid in evaluating if adherence to the ERAS protocol is achieved.
189 studies on the registry are indexed under Urinary Bladder, Neurogenic; 40 are open to participants now.
This study's planned enrollment of 85 is above the median of 71 across 57 observational studies indexed under Urinary Bladder, Neurogenic.
Browse Urinary Bladder, Neurogenic studies →Washington University School of Medicine is the lead sponsor of 1,803 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
There are 2 populations:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Prospectively enrolled group to receive standardized care under a set ERAS protocol/pathway.
Other: Enhanced Recovery after Surgery
Recent historical patients (5 years prior to start of ERAS) that will be propensity-matched to ERAS patients to be used as controls for comparison of outcomes.
Other: Historical usual surgical care
Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
Recent historical controls will have received care under "usual care" that existed prior to implementation of an enhanced recovery protocol.
Adherence to ERAS protocol
Adherence to ERAS protocol items with # of items achieved (out of 20)
Time frame: 3 years
Length of stay
Median primary inpatient hospital stay associated with surgery episode (# midnight)
Time frame: 3 years
Re-admissions within 30 days
Median number of re-admissions to any hospital within 30 days of surgery episode per patient
Time frame: 30 days
Re-operations within 90 days
Median number of unplanned re-operations within 90 days of surgery episode per patient
Time frame: 90 days
Number of visits to the emergency room within 90 day period
Median number of visits to any emergency room within 90 days of surgery episode per patient
Time frame: 90 days
Number of 30-day complications
Median number of 30-day complications by Clavien-Dindo classification per patient
Time frame: 3 years
Number of 90-day complications
Median number of 90-day complications by Clavien-Dindo classification per patient
Time frame: 3 years
Number of long-term complications within 1 year
Median number of long-term complications per patient
Time frame: 1 year
Daily IV morphine equivalents
Mean daily IV morphine equivalents (mg/kg) usage during first 3 days after surgery
Time frame: 3 days after surgery
Plan to share: No
Started Apr 2017 (actual). Primary completion is estimated for Oct 2026, 114 months after the start.
Of 26 observational studies under Urinary Bladder, Neurogenic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 61. This study's planned 114 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →